CLAIMS

1. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment of infections caused by pathogenic *Enterobacteriaceae*, wherein the bacterial strain is able to convert H_2/CO_2 to acetate.

2. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment of *E. coli* infection, wherein the bacterial strain is able to convert H_2/CO_2 to acetate.

3. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment of infections caused by pathogenic *Enterobacteriaceae*.

4. Use of a composition comprising a bacterial strain that has a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 in the manufacture of a medicament for the treatment of *E. coli* infection.

5. The composition use of any one of claims 1-4, wherein the bacterial strain has a 16s rRNA sequence that is at least 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5 or which has the 16s rRNA sequence of SEQ ID NO:5 or wherein the bacterial strain is *Blautia hydrogenotrophica*.

6. The use of any one of claims 1-4, wherein the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of *Blautia stercoris* or *Blautia wexlerae*; or wherein the bacterial strain is *Blautia stercoris* or *Blautia wexlerae*.

7. The use of any preceding claim, wherein the medicament is to be administered orally and/or comprises one or more pharmaceutically acceptable excipients or carriers.

8. The use of any preceding claim, wherein the bacterial strain is lyophilised and/or viable.

9. The use of any preceding claim, wherein the composition comprises a single bacterial strain having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, wherein the bacterial strain is able to convert H_2/CO_2 to acetate or wherein the composition comprises a single bacterial strain having a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5.

10. The use of any one of claims 1-8, wherein the composition comprises a bacterial strain having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, wherein the bacterial strain is able to convert H_2/CO_2 to acetate as part of a microbial consortium or the composition comprises a bacterial strain having a 16s rRNA sequence that is at least 97% identical to SEQ ID NO:5 as part of a microbial consortium.

11. The use of any preceding claim, wherein the medicament is a food product and/or a vaccine composition.